| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000028600 |
| Receipt No. | R000032736 |
| Official scientific title of the study | Evaluation of the effect of lactic acid bacteria on glucose metabolism in subjects with borderline diabetes |
| Date of disclosure of the study information | 2017/08/10 |
| Last modified on | 2019/01/24 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Evaluation of the effect of lactic acid bacteria on glucose metabolism in subjects with borderline diabetes | |
| Title of the study (Brief title) | Evaluation of the effect of lactic acid bacteria on glucose metabolism in subjects with borderline diabetes | |
| Region |
|
|
| Condition | ||
| Condition | Healthy volunteers | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the effect of Pediococcus pentosaceus LP28 on impaired glucose tolerance. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | 12-week change in OGTT-2h |
| Key secondary outcomes | 12-week changes in AUC, Cmax and Tmax of blood glucose and insulin in OGTT, insulinogenic index, FBS, HOMA-R, HbA1c, glycoalbumin, visceral fat area, body fat percentage, abdominal circumference |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | YES |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake of granulated powder containing Pediococcus pentosaceus LP28 and dextrin (2 g/day) for 12 weeks. | |
| Interventions/Control_2 | Intake of granulated powder of dextrin (2 g/day) for 12 weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 140<= OGTT-2h <200 mg/dL | |||
| Key exclusion criteria | 1) HbA1c>=6.5%
2) Taking medicines or receiving health guidance for hypertension, diabetes, and/or hyperlipidemia 3) Taking drugs or functional food that may affect the trial 4) Participation in any clinical trial within 90 days of the commencement of the trial 5) In pregnancy or nursing a child 6) Judged as ineligible by clinical investigators |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Fumiko Higashikawa |
| Organization | Hiroshima University, Institute of Biomedical & Health Sciences |
| Division name | Project Research Center for Clinical Trial and Preventive Medicine |
| Address | Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, JAPAN |
| TEL | 082-257-1533 |
| fumiko@hiroshima-u.ac.jp | |
| Public contact | |
| Name of contact person | Fumiko Higashikawa |
| Organization | Hiroshima University, Institute of Biomedical & Health Sciences |
| Division name | Project Research Center for Clinical Trial and Preventive Medicine |
| Address | Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, JAPAN |
| TEL | 082-257-1533 |
| Homepage URL | |
| fumiko@hiroshima-u.ac.jp | |
| Sponsor | |
| Institute | Hiroshima University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ministry of Education, Culture, Sports, Science and Technology |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 広島大学病院(広島県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032736 |